[go: up one dir, main page]

MX365513B - Forma de dosificacion de dispersion rapida que contiene levetiracetam. - Google Patents

Forma de dosificacion de dispersion rapida que contiene levetiracetam.

Info

Publication number
MX365513B
MX365513B MX2015012134A MX2015012134A MX365513B MX 365513 B MX365513 B MX 365513B MX 2015012134 A MX2015012134 A MX 2015012134A MX 2015012134 A MX2015012134 A MX 2015012134A MX 365513 B MX365513 B MX 365513B
Authority
MX
Mexico
Prior art keywords
dosage form
levetiracetam
form containing
containing levetiracetam
disperse dosage
Prior art date
Application number
MX2015012134A
Other languages
English (en)
Other versions
MX2015012134A (es
Inventor
Nemichand B Jain
Henry L Surprenant
Thomas G West
Jules Jacob
Norman Coyle
Donald C Monkhouse
Original Assignee
Aprecia Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprecia Pharmaceuticals LLC filed Critical Aprecia Pharmaceuticals LLC
Publication of MX2015012134A publication Critical patent/MX2015012134A/es
Publication of MX365513B publication Critical patent/MX365513B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se da a conocer una forma de dosificación impresa tridimensioalmente que se dispersa rápidamente de dosis altas que comprende una dosis alta de levetiracetam en una matriz porosa que se dispersa en agua dentro de un período menor que aproximadamente 10 segundos. También se dan a conocer métodos para preparar la forma de dosificación y para tratar una condición, enfermedad o trastorno que es sensible terapéuticamente al levetiracetam. También se proporciona un proceso para preparar la forma de dosificación.
MX2015012134A 2013-03-15 2014-03-14 Forma de dosificacion de dispersion rapida que contiene levetiracetam. MX365513B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791444P 2013-03-15 2013-03-15
PCT/US2014/028954 WO2014144512A1 (en) 2013-03-15 2014-03-14 Rapid disperse dosage form containing levetiracetam

Publications (2)

Publication Number Publication Date
MX2015012134A MX2015012134A (es) 2016-02-03
MX365513B true MX365513B (es) 2019-06-06

Family

ID=51537722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012134A MX365513B (es) 2013-03-15 2014-03-14 Forma de dosificacion de dispersion rapida que contiene levetiracetam.

Country Status (10)

Country Link
US (2) US20220211668A1 (es)
EP (2) EP3431141B1 (es)
JP (3) JP6170234B2 (es)
CN (2) CN105188849B (es)
AU (2) AU2014228990B2 (es)
CA (1) CA2906029C (es)
ES (2) ES2688880T3 (es)
HK (1) HK1216513A1 (es)
MX (1) MX365513B (es)
WO (1) WO2014144512A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
JP6170234B2 (ja) 2013-03-15 2017-07-26 アプレシア・ファーマスーティカルズ・カンパニー レベチラセタムを含む急速に分散する剤形
US10653622B1 (en) 2015-04-13 2020-05-19 Pharmacoustics Technologies LLC Individualized solid dosage products and a system and method for the globally integrated pharmaceutical manufacturing and its monitoring thereof
EP4512394A2 (en) 2015-06-03 2025-02-26 Triastek, Inc. Dosage forms and use thereof
CA3036138A1 (en) 2016-09-09 2018-03-15 Merck Patent Gmbh Process for the manufacture of a solid pharmaceutical adminstration form
WO2018137686A1 (en) 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2018156141A1 (en) 2017-02-24 2018-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional (3d) printing a pharmaceutical tablet
EP3592337B1 (en) 2017-03-08 2023-07-05 Cinrx Pharma, LLC Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP3605681A4 (en) 2017-03-31 2020-12-30 NIPPON STEEL Chemical & Material Co., Ltd. CARBONATED CATALYST SUPPORT MATERIAL FOR A SOLID POLYMER FUEL CELL AND ITS MANUFACTURING PROCESS
WO2018230329A1 (ja) * 2017-06-16 2018-12-20 丸石製薬株式会社 レベチラセタム含有ゲル経口医薬組成物
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
JP7264711B2 (ja) * 2019-04-26 2023-04-25 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法
EP3975987A1 (de) 2019-05-31 2022-04-06 DiHeSys Digital Health Systems GmbH Pharmazeutische darreichungsformen und verfahren zu deren herstellung
TWI734309B (zh) 2019-12-19 2021-07-21 水星生醫股份有限公司 滲透性噴塗製作藥錠裝置
CN111840243B (zh) * 2020-07-30 2021-11-30 中国人民解放军军事科学院军事医学研究院 一种左乙拉西坦3d打印制剂及其制备方法
CN113599362A (zh) * 2021-01-15 2021-11-05 中国人民解放军军事科学院军事医学研究院 一种3d打印制剂及其制备方法和其应用

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
CH660750A5 (en) * 1984-11-06 1987-06-15 Thomae Gmbh Dr K Physiologically acceptable inks for printing mouldings having a porous surface by inkjet writing means
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5121329A (en) 1989-10-30 1992-06-09 Stratasys, Inc. Apparatus and method for creating three-dimensional objects
US5204055A (en) 1989-12-08 1993-04-20 Massachusetts Institute Of Technology Three-dimensional printing techniques
US5387380A (en) 1989-12-08 1995-02-07 Massachusetts Institute Of Technology Three-dimensional printing techniques
US5127037A (en) 1990-08-15 1992-06-30 Bynum David K Apparatus for forming a three-dimensional reproduction of an object from laminations
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5252264A (en) 1991-11-08 1993-10-12 Dtm Corporation Apparatus and method for producing parts with multi-directional powder delivery
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5641561A (en) 1992-08-17 1997-06-24 Weyerhaeuser Company Particle binding to fibers
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5490882A (en) 1992-11-30 1996-02-13 Massachusetts Institute Of Technology Process for removing loose powder particles from interior passages of a body
US6146567A (en) 1993-02-18 2000-11-14 Massachusetts Institute Of Technology Three dimensional printing methods
CA2166891C (en) 1993-07-09 2001-07-03 Sang K. Wong Method for making freeze dried drug dosage forms
US6280771B1 (en) 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US5518680A (en) 1993-10-18 1996-05-21 Massachusetts Institute Of Technology Tissue regeneration matrices by solid free form fabrication techniques
US5490962A (en) 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5879489A (en) 1993-11-24 1999-03-09 Burns; Marshall Method and apparatus for automatic fabrication of three-dimensional objects
WO1995034468A1 (en) 1994-06-14 1995-12-21 Soligen, Inc. Powder handling apparatus for additive fabrication equipment
JPH0892105A (ja) 1994-09-26 1996-04-09 Ota Seiyaku Kk 速溶性の経口投与用アルギン酸ナトリウム固形製剤
US5717599A (en) 1994-10-19 1998-02-10 Bpm Technology, Inc. Apparatus and method for dispensing build material to make a three-dimensional article
CA2134611C (en) 1994-10-28 2002-12-24 Richard John Yarwood Process for preparing solid pharmaceutical dosage forms
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US6270335B2 (en) 1995-09-27 2001-08-07 3D Systems, Inc. Selective deposition modeling method and apparatus for forming three-dimensional objects and supports
US5660621A (en) 1995-12-29 1997-08-26 Massachusetts Institute Of Technology Binder composition for use in three dimensional printing
US6596224B1 (en) 1996-05-24 2003-07-22 Massachusetts Institute Of Technology Jetting layers of powder and the formation of fine powder beds thereby
US5902441A (en) 1996-09-04 1999-05-11 Z Corporation Method of three dimensional printing
BR9705156A (pt) 1996-10-25 2000-01-04 Massachusetts Inst Technology Processo e sistema de fabricar um componente que consiste em partes constituìdas de diferentes materiais
US6007318A (en) 1996-12-20 1999-12-28 Z Corporation Method and apparatus for prototyping a three-dimensional object
US6989115B2 (en) 1996-12-20 2006-01-24 Z Corporation Method and apparatus for prototyping a three-dimensional object
US7037382B2 (en) 1996-12-20 2006-05-02 Z Corporation Three-dimensional printer
CA2281473C (en) 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
AU735039B2 (en) 1997-03-31 2001-06-28 Therics, Inc. Method for dispensing of powders
US6213168B1 (en) 1997-03-31 2001-04-10 Therics, Inc. Apparatus and method for dispensing of powders
US5940674A (en) 1997-04-09 1999-08-17 Massachusetts Institute Of Technology Three-dimensional product manufacture using masks
JP3615376B2 (ja) 1997-12-15 2005-02-02 富士写真フイルム株式会社 被印刷体の色補正方法およびその装置
US6322728B1 (en) 1998-07-10 2001-11-27 Jeneric/Pentron, Inc. Mass production of dental restorations by solid free-form fabrication methods
US6808659B2 (en) 1998-07-10 2004-10-26 Jeneric/Pentron Incorporated Solid free-form fabrication methods for the production of dental restorations
US6821462B2 (en) 1998-07-10 2004-11-23 Jeneric/Pentron, Inc. Mass production of shells and models for dental restorations produced by solid free-form fabrication methods
US6363606B1 (en) 1998-10-16 2002-04-02 Agere Systems Guardian Corp. Process for forming integrated structures using three dimensional printing techniques
EP1124688B1 (en) 1998-10-29 2004-04-07 Z Corporation Three dimensional printing material system and method
US6547994B1 (en) 1998-11-13 2003-04-15 Therics, Inc. Rapid prototyping and manufacturing process
US6165406A (en) 1999-05-27 2000-12-26 Nanotek Instruments, Inc. 3-D color model making apparatus and process
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
US6658314B1 (en) 1999-10-06 2003-12-02 Objet Geometries Ltd. System and method for three dimensional model printing
DE19948591A1 (de) 1999-10-08 2001-04-19 Generis Gmbh Rapid-Prototyping - Verfahren und - Vorrichtung
US20030173695A1 (en) * 1999-11-12 2003-09-18 Therics, Inc. Rapid prototyping and manufacturing process
US20050104241A1 (en) 2000-01-18 2005-05-19 Objet Geometried Ltd. Apparatus and method for three dimensional model printing
US6850334B1 (en) 2000-01-18 2005-02-01 Objet Geometries Ltd System and method for three dimensional model printing
US6360656B2 (en) 2000-02-28 2002-03-26 Minolta Co., Ltd. Apparatus for and method of printing on three-dimensional object
US7300619B2 (en) 2000-03-13 2007-11-27 Objet Geometries Ltd. Compositions and methods for use in three dimensional model printing
US20030207959A1 (en) 2000-03-13 2003-11-06 Eduardo Napadensky Compositions and methods for use in three dimensional model printing
US6772026B2 (en) 2000-04-05 2004-08-03 Therics, Inc. System and method for rapidly customizing design, manufacture and/or selection of biomedical devices
WO2001078969A2 (en) * 2000-04-14 2001-10-25 Z Corporation Compositions for three-dimensional printing of solid objects
US20010050031A1 (en) 2000-04-14 2001-12-13 Z Corporation Compositions for three-dimensional printing of solid objects
CA2408956C (en) 2000-05-18 2011-07-12 Therics, Inc. Method and form of a drug delivery device,such as encapsulating a toxic core within a non-toxic region in an oral dosage form
JP3546846B2 (ja) 2001-01-22 2004-07-28 セイコーエプソン株式会社 印刷装置
GB0103754D0 (en) 2001-02-15 2001-04-04 Vantico Ltd Three-dimensional structured printing
GB2376920A (en) 2001-06-27 2002-12-31 Inca Digital Printers Ltd Inkjet printing on a three-dimensional object including relative movement of a printhead and the object during printing about a rotational axis
US20030041962A1 (en) 2001-09-05 2003-03-06 John R. Johnson Digitally printed products and process
ATE322972T1 (de) 2001-10-29 2006-04-15 Therics Inc System und verfahren zum uniaxialen pressen eines gegenstandes wie eine drei-dimensional gedruckte dosierungsform
US6945638B2 (en) 2001-10-29 2005-09-20 Therics, Inc. Method and system for controlling the temperature of a dispensed liquid
EP1441703B1 (en) 2001-10-29 2018-01-03 Massachusetts Institute of Technology Zero-order release profile dosage form manufactured by three-dimensional printing
US7411008B2 (en) 2001-11-07 2008-08-12 Novartis Ag Ink formulations and uses thereof
GB0127252D0 (en) 2001-11-13 2002-01-02 Vantico Ag Production of composite articles composed of thin layers
US20030151167A1 (en) 2002-01-03 2003-08-14 Kritchman Eliahu M. Device, system and method for accurate printing of three dimensional objects
KR20040098009A (ko) 2002-03-06 2004-11-18 교와 핫꼬 고교 가부시끼가이샤 구강 내 속붕괴성 정제
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
WO2003092633A2 (en) 2002-05-06 2003-11-13 Massachusetts Institute Of Technology Diffusion-controlled dosage form and method of fabrication including three dimensional printing
FI111922B (fi) 2002-05-31 2003-10-15 Perlos Oyj Menetelmä kolmiulotteisten pintojen kuviointiin
CZ297082B6 (cs) 2002-06-03 2006-09-13 Ing. Ilja Krejcí-Engineering Soucástky s trojrozmernou strukturou pripravené tlustovrstvou technologií a zpusob jejich výroby
US6905645B2 (en) 2002-07-03 2005-06-14 Therics, Inc. Apparatus, systems and methods for use in three-dimensional printing
US20040038009A1 (en) * 2002-08-21 2004-02-26 Leyden Richard Noel Water-based material systems and methods for 3D printing
US20060111807A1 (en) 2002-09-12 2006-05-25 Hanan Gothait Device, system and method for calibration in three-dimensional model printing
DE10261983A1 (de) 2002-09-21 2004-04-08 Koenig & Bauer Ag Verfahren zum Einstellen des Anpressdrucks einer verstellbar gelagerten Walze
US7087109B2 (en) 2002-09-25 2006-08-08 Z Corporation Three dimensional printing material system and method
US20040112523A1 (en) 2002-10-15 2004-06-17 Crom Elden Wendell Three dimensional printing from two dimensional printing devices
EP1581902B1 (en) 2002-11-12 2008-04-23 Objet Geometries Ltd. METHOD AND SYSTEM FOR THREE-DIMENSIONAL OBJECT PRINTING& x9;& x9;
EP1581076B1 (en) 2002-11-13 2012-04-25 MiiC America, Inc. A system and process for creating custom fit artificial fingernails using a non-contact optical measuring device
EP1590149B1 (en) 2002-12-03 2008-10-22 Objet Geometries Ltd. Process of and apparatus for three-dimensional printing
US7589868B2 (en) 2002-12-11 2009-09-15 Agfa Graphics Nv Method and apparatus for creating 3D-prints and a 3-D printing system
AU2003900180A0 (en) 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
WO2004078069A2 (en) 2003-03-05 2004-09-16 Therics, Inc. Process for manufacturing biomedical articles by infiltrating biocompatible metal alloys in porous matrices
CN1819819B (zh) 2003-05-07 2011-03-09 株式会社三养社 用于制备速熔片的高度可塑性颗粒
WO2004106041A2 (en) 2003-05-23 2004-12-09 Z Corporation Apparatus and methods for 3d printing
GB0312909D0 (en) 2003-06-05 2003-07-09 Univ Liverpool Apparatus for manufacturing three dimensional items
WO2005007390A1 (en) 2003-07-14 2005-01-27 Therics, Inc. Three-dimensional printing apparatus and methods of manufacture including sterilization or disinfection, for example, using ultraviolet light
FR2858556B1 (fr) 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US20050059757A1 (en) 2003-08-29 2005-03-17 Z Corporation Absorbent fillers for three-dimensional printing
FR2859128B1 (fr) 2003-08-29 2006-03-10 Centre Nat Rech Scient Procede et dispositif de fabrication d'un composant multimateriaux tridimensionnel par impression du type jet d'encre
US7220380B2 (en) 2003-10-14 2007-05-22 Hewlett-Packard Development Company, L.P. System and method for fabricating a three-dimensional metal object using solid free-form fabrication
US7365129B2 (en) 2003-10-14 2008-04-29 Hewlett-Packard Development Company, L.P. Polymer systems with reactive and fusible properties for solid freeform fabrication
US7806499B2 (en) 2004-02-06 2010-10-05 Nagayama Ip Holdings Llc Complex pointillistic printing
US7407250B2 (en) 2004-02-18 2008-08-05 Pixal Wizard International, Inc Apparatus, system, and method for multi-dimensional registration printing
US7383768B2 (en) 2004-05-05 2008-06-10 Awi Licensing Company Rapid prototyping and filling commercial pipeline
KR101202681B1 (ko) 2004-05-27 2012-11-19 스미토모덴키고교가부시키가이샤 인쇄용 블럭 공중합 폴리이미드 잉크 조성물
KR100606457B1 (ko) 2004-11-11 2006-11-23 한국기계연구원 3차원 프린팅 조형시스템
EP1827391B1 (en) * 2004-11-26 2015-09-23 Aprecia Pharmaceuticals Co. Three dimensionally printed dosage forms
CA2595988A1 (en) * 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
EP1871363A4 (en) 2005-03-30 2009-01-21 Genpharm Inc COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
MX2007004294A (es) 2005-07-26 2008-03-11 Ucb Pharma Sa Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
EP1759791A1 (en) 2005-09-05 2007-03-07 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Apparatus and method for building a three-dimensional article
CN101326046A (zh) 2005-09-20 2008-12-17 Pts软件公司 建造三维产品的设备以及建造三维产品的方法
JP4227642B2 (ja) 2005-12-28 2009-02-18 キヤノン株式会社 立体物の製造方法、及び立体物の製造装置
US7978363B2 (en) 2006-02-15 2011-07-12 Seiko Epson Corporation Printing apparatus and printing method
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20090208576A1 (en) * 2006-03-31 2009-08-20 Gandhi Anilkumar S Orally Disintegrating Tablets
EP2024168B1 (en) 2006-05-26 2012-08-22 3D Systems, Inc. Apparatus, method and multiport valve for handling powder in a 3-d printer
EP2056792B1 (en) * 2006-08-31 2023-06-07 Adare Pharmaceuticals, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs
JP2008114493A (ja) 2006-11-06 2008-05-22 Mimaki Engineering Co Ltd 三次元プリンタ
EP2664442B1 (en) 2006-12-08 2018-02-14 3D Systems Incorporated Three dimensional printing material system
ES2526171T3 (es) * 2006-12-14 2015-01-07 Novartis Ag Adsorbente de fosfato a base de hierro (III)-carbohidratos
WO2008086033A1 (en) 2007-01-10 2008-07-17 Z Corporation Three-dimensional printing material system with improved color, article performance, and ease of use
JP2008183778A (ja) 2007-01-29 2008-08-14 Seiko Epson Corp ２次元コード印刷方法、そのプログラム及びインクジェットプリンタ
WO2008103450A2 (en) 2007-02-22 2008-08-28 Z Corporation Three dimensional printing material system and method using plasticizer-assisted sintering
US7655163B2 (en) 2007-05-09 2010-02-02 Sanwa Screen Co., Ltd. Manufacturing method of film insert molded article
EP2197428B1 (en) 2007-10-16 2012-01-25 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
MX2010005861A (es) * 2007-11-30 2010-06-11 Pfizer Ltd Agonistas novedosos de los receptores de glucocorticoides.
CL2008003827A1 (es) * 2007-12-21 2009-07-24 Aptalis Pharmatech Inc Composicion para tabletas de desintegracion oral que comprende al menos una droga ( temazepam), 0,5-3% de un polimero aglutinanete para odt, un alcohol de azucar y/o sacarido, y un desintegrante; metodo para prepararla; util para tratar una enfermedad o condicion como un trastorno del sueño en pacientes con disfagia..
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
CN101269052B (zh) * 2008-03-27 2010-06-23 东华大学 口腔速溶速效药膜及其三维打印制备方法
WO2009124357A1 (en) * 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
CN101439584B (zh) * 2008-08-29 2011-03-23 东华大学 一种微乳液体黏结剂三维打印系统可打印性能的测定方法
HUE040119T2 (hu) * 2009-10-01 2019-02-28 Adare Pharmaceuticals Inc Orálisan alkalmazott kortikoszteroid készítmények
US20110105441A1 (en) 2009-10-30 2011-05-05 Fmc Corporation Stable Orally Disintegrating Tablets Having Low Superdisintegrant
CN102085194B (zh) 2009-12-08 2013-12-25 北京以岭生物工程技术有限公司 左乙拉西坦口腔崩解片及其制备方法
EP2563340A2 (en) * 2010-04-26 2013-03-06 Mahmut Bilgic Water soluble pharmaceutical composition
US20110318390A1 (en) * 2010-06-28 2011-12-29 Fuisz Richard C Bioactive Dose Having a Rapid Release Coating or Rapid Release Layer Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive
CN102093646B (zh) * 2010-10-29 2012-07-18 华南理工大学 一种用于三维打印快速成型的材料及其制备方法
US8426461B2 (en) * 2011-01-17 2013-04-23 Takeda Pharmaceutical Company Limited Orally dispersible tablet
WO2014143935A1 (en) 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of oxcarbazepine
US9339489B2 (en) * 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
JP6170234B2 (ja) 2013-03-15 2017-07-26 アプレシア・ファーマスーティカルズ・カンパニー レベチラセタムを含む急速に分散する剤形
CA2906172C (en) 2013-03-15 2021-12-21 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of topiramate

Also Published As

Publication number Publication date
CA2906029A1 (en) 2014-09-18
EP2968994A4 (en) 2016-03-16
JP6640069B2 (ja) 2020-02-05
WO2014144512A4 (en) 2014-11-13
CN109908355B (zh) 2022-11-15
EP3431141B1 (en) 2021-12-08
JP6170234B2 (ja) 2017-07-26
AU2014228990B2 (en) 2017-02-02
JP2016514680A (ja) 2016-05-23
CA2906029C (en) 2017-09-05
WO2014144512A1 (en) 2014-09-18
CN105188849B (zh) 2019-01-15
HK1214787A1 (en) 2016-08-05
AU2014228990A1 (en) 2015-10-08
CN109908355A (zh) 2019-06-21
AU2017202752B2 (en) 2018-07-26
CN105188849A (zh) 2015-12-23
ES2908292T3 (es) 2022-04-28
JP6788633B2 (ja) 2020-11-25
MX2015012134A (es) 2016-02-03
US20230069979A1 (en) 2023-03-09
US12396979B2 (en) 2025-08-26
AU2017202752A1 (en) 2017-05-18
US20220211668A1 (en) 2022-07-07
EP3431141A1 (en) 2019-01-23
EP2968994B1 (en) 2018-08-15
ES2688880T3 (es) 2018-11-07
JP2018162276A (ja) 2018-10-18
HK1216513A1 (zh) 2016-11-18
JP2017071626A (ja) 2017-04-13
EP2968994A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
MX365513B (es) Forma de dosificacion de dispersion rapida que contiene levetiracetam.
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
BR112012027780A2 (pt) sistema, artigo de fabricação, e, meio legível por computador
BR112015014619A2 (pt) tratamento de transtornos do ritmo circadiano
DOP2017000105A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112014018433A8 (pt) Métodos para determinar o período circadiano em um indivíduo humano e um tau de um paciente, para tratar um paciente humano, para fornecer informação relativa a um ritmo circadiano do paciente, e para converter dados da concentração de melatonina ou substituto de melantonina nos dados do ritmo circadiano, sistema, e, meio de armazenagem legível por computador
BR112015018418A2 (pt) métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
CL2013001982A1 (es) Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
MX2015013784A (es) C. novyi para el tratamiento de tumores solidos en humanos.
CY1119793T1 (el) Θεραπεια συνδυασμου σταθερων δοσεων της νοσου parkinson
BR112015022749A2 (pt) reator de esterilização e método
BR112017011777A2 (pt) antagonista de a2a de dosagem baixa para o tratamento de tdah e doença de parkinson
BR112015008839A2 (pt) tratamento de tumores do sistema nervoso central
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
PE20142020A1 (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
Kumar et al. Drug utilization in clinical conditions: an update on its essentials.
BR112015030388A2 (pt) formulação farmacêutica
RS54325B1 (en) PHARMACEUTICAL COMPOUNDS CONTAINING BETA GALACTOSIDASE AND ALPHA GALACTOSIDASE AND THEIR USE FOR THE TREATMENT OF GASTROESOFAGEAL REFLUX DISEASE
MENG Clinical study of the effects of edaravone and Ozagrel in the treatment of 30 patients with acute ischemic stroke
GUO The pharmacoeconomic evaluations of four drugs in the treatment of bacterial vaginitis
YAO Effect of itraconazole capsules combined with clotrimazole vaginal tablets on patients with fungal vaginitis

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: APRECIA PHARMACEUTICALS LLC

FG Grant or registration